The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $282.69

Today's change+22.05 +8.46%
Updated March 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $282.69

Today's change+22.05 +8.46%
Updated March 26 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc crosses above 20-day moving average

Intercept Pharmaceuticals Inc closed up sharply Thursday, rallying (U.S.)$22.05 or 8.46% to (U.S.)$282.69 and crossing above its 20-day moving average. Shares have lost 2.02% over the last five days, but have gained 81.21% over the last year to date. This security has underperformed the S&P 500 by 23.28% during the last year.

Key company metrics

  • Open(U.S.) $257.01
  • Previous close(U.S.) $260.64
  • High(U.S.) $295.01
  • Low(U.S.) $252.95
  • Bid / Ask-- / --
  • YTD % change+81.21%
  • Volume1,906,600
  • Average volume (10-day)855,335
  • Average volume (1-month)738,638
  • Average volume (3-month)625,593
  • 52-week range(U.S.) $128.50 to (U.S.) $360.10
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$13.75
Updated March 26 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense36372320
Selling / general / administrative12986
Research & development24271514
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-35-36-22-20
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-35-3633-246
Income after tax-35-3633-246
Income tax, total----00
Net income-35-3633-246
Total adjustments to net income--------
Net income before extra. items-35-3633-246
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-35-3633-246
Inc. avail. to common incl. extra. items-35-3633-246
Diluted net income-35-3633-246
Dilution adjustment--------
Diluted weighted average shares21212221
Diluted EPS excluding extraordinary itemsvalue per share-1.63-1.691.51-11.94
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-1.63-1.691.51-11.94